Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Carcinoma, Medullary 9Lung Neoplasms 8Thyroid Neoplasms 7Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Ovarian Neoplasms 3Carcinoma, Renal Cell 3Breast Neoplasms 3Stomach Neoplasms 2Pleural Effusion 2Kidney Neoplasms 2Gliosarcoma 2Glioblastoma 2Familial medullary thyroid carcinoma 2Fallopian Tube Neoplasms 2Urinary Bladder Neoplasms 1Thyroid cancer, medullary 1Thyroid Diseases 1Thyroid Cancer, Papillary 1Small Cell Lung Carcinoma 1Recurrence 1Rectal Neoplasms 1Precancerous Conditions 1Peritoneal Neoplasms 1Oligodendroglioma 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1

Interventions

pembrolizumab 26atezolizumab 14Nivolumab 13Gemcitabine 13Cisplatin 10Docetaxel 8Carboplatin 8avelumab 7Mitomycin 7epacadostat 4cabozantinib 4Ipilimumab 4pemigatinib 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Bevacizumab 3vofatamab 2rucaparib 2lenvatinib 2enfortumab vedotin 2durvalumab 2cabazitaxel 2bempegaldesleukin 2Standard of Care 2Rogaratinib 2Ramucirumab 2Radiation 2Platinum 2Pemetrexed 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Transitional Cell × vandetanib × Clear all
NCT00880334 2018-09-18

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Dana-Farber Cancer Institute

Phase 2 Completed
149 enrolled 12 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡